Singular Genomics is inventing at the forefront of genomics, one of the world’s fastest-growing industries. We are a publicly traded life science technology company that is leveraging novel, next-generation sequencing (NGS) and multi-omics technologies to build products that empower researchers and clinicians. The G4 Sequencing Platform, our first commercially available product, is a powerful, highly versatile benchtop genomic sequencer designed to produce fast and accurate results. In development, the PX system leverages Singular’s proprietary sequencing technology, applying it as an in-situ readout to look at RNA and proteins in single cells and tissue. We are committed to unlocking the potential of our core technologies to reshape the future of genomics. We offer a dynamic, fast-paced, results-oriented environment where employees can make a significant impact in a rapidly expanding company. Innovation, continuous learning, multi-disciplinary collaboration, and diversity of thought are pillars of our culture.
